Biotech licenses protein production tech to Eli Lilly

By Maggie Lynch

- Last updated on GMT

(Image: Getty/peopleimages)
(Image: Getty/peopleimages)

Related tags Protein Eli lilly Eli lilly and company Technology Dna processing development

ProteoNic licenses its 2G UNic technology to Eli Lilly for the development of the latter’s proprietary products.

Per the agreement, Eli Lilly receives non-exclusive commercial rights for the application of ProteoNic’s recombinant protein production technology. The licensee company will use this technology for future product development.

2G UNic is a mammalian protein expression technology designed to improve recombinant cell line production levels in host cells, selection systems, and protein targets. According to ProteoNic, this technology exerts a positive effect on recombinant protein production levels and on the stability of expression.

Additionally, ProteoNic licensed the same protein production technology to Aragen Bioscience. While ProteoNic was not able to provide further comment on its deal with Eli Lilly, ProteoNic’s spokesperson Victor Schut told us about the platform at the time of its deal with Aragen.

Schut told us, “We incorporate our DNA elements into existing client production vectors as an improvement of those vectors and production cell lines or we supply our own complete vectors. Both approaches result in higher protein production yields.”

Previously ProteoNic licensed​ a vector gene delivery system to Horizon Discovery. The licensed technology, CHOGUN, introduces genetic materials into CHO cells that lack the gene encoding enzyme glutamine synthetase, without using the toxic methionine sulphoximine material that is used in the traditional process.

Financial details of the agreement with Eli Lilly were not disclosed.

Related news

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more